Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study
BioDrugs · 2025
DOI: 10.1007/s40259-025-00746-w ↗Kurz gefasst
Qualitative Studie in der Zeitschrift BioDrugs, 2025. Verfasst von Elif Car und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Drug Development. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL) Fund.
Abstract (Originalsprache)
OBJECTIVES: This study aims to assess perspectives of stakeholders on scientific and regulatory challenges associated with biosimilarity demonstration and to formulate consensus-based recommendations to foster regulatory convergence and streamline biosimilar development globally. METHODS: A modified Nominal Group Technique with an international panel of regulators, academics, and industry representatives involved three phases: (i) first individual grading, (ii) focus group discussions, and (iii) second individual grading. High consensus was defined as ≥80% agreement with a weighted mean score of ≥ 4.0. RESULTS: Overall, four focus groups were held in September 2023 with 21 participants (2 academics, 7 regulators, and 12 industry representatives). In total, 22 recommendations were proposed, with 16 obtaining high consensus. Highest-rated recommendations included enhancing stakeholder education on science-based biosimilarity principles (mean score: 4.65/5), promoting regulatory convergence through reliance (mean score: 4.65/5), aligning regulatory requirements based on current scientific knowledge (mean score: 4.60/5), reconsidering the requirement for comparative clinical efficacy studies (mean score: 4.65/5), harmonizing reference product selection criteria (mean score: 4.55/5), facilitating proactive knowledge sharing among regulators (mean score: 4.50/5), eliminating in vivo animal studies (mean score: 4.50/5), and accepting clinical studies conducted for global submissions (mean score: 4.50/5). Two recommendations received the lowest consensus: providing incentives for the development of new pharmacodynamic biomarkers (mean score: 2.80/5) and developing distinct International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines for biosimilar assessment (mean score: 3.20/5). CONCLUSIONS: The consensus-based recommendations identified in this study outline priority areas and measures for streamlining biosimilar development and fostering regulatory convergence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- , Brixlegg, Austria.
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. a.vulto@erasmusmc.nl.
- Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands. a.vulto@erasmusmc.nl.
Förderung
- Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL) Fund
Zitieren
APA
Car, E., Barbier, L., Schwarzenberger, I., Huys, I., Simoens, S., & Vulto, A. G. (2025). Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study. BioDrugs. https://doi.org/10.1007/s40259-025-00746-w
Vancouver
Car E, Barbier L, Schwarzenberger I, Huys I, Simoens S, Vulto AG. Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study. BioDrugs. 2025. doi:10.1007/s40259-025-00746-w
BibTeX
@article{Car2025,
author = {Car, Elif and Barbier, Liese and Schwarzenberger, Ingrid and Huys, Isabelle and Simoens, Steven and Vulto, Arnold G},
title = {Toward Regulatory Convergence and Streamlined Biosimilar Development: Recommendations from an International Qualitative Study},
journal = {BioDrugs},
year = {2025},
doi = {10.1007/s40259-025-00746-w}
}
EUVIMED